Alphamab Oncology (Stock code: 9966.HK) is an innovative biopharmaceutical company focusing on oncology therapeutics. By leveraging its proprietary core technology platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payload, dual-payload antibody conjugation, and subcutaneous high concentration formulation for biologics, the Company has established a differentiated and globally competitive product portfolio, covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies.
The Company has one product approved for marketing (Envafolimab, the world's first subcutaneously injectable PD-(L)1 inhibitor), which has made a significant breakthrough in the convenience and accessibility of cancer treatment. Additionally, the Company has multiple bispecific antibodies and bispecific ADCs in clinical stage, while rapidly advancing the preclinical pipeline prioritizing bispecific ADCs and dual-payload ADCs. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, ArriVent, and Glenmark.
Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs to benefit patients.
Company Details
- Employees
- 27
- Founded
- -
- Address
- 苏州市, 江苏省 215028, Cn
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.alphamabonc.com
- Keywords
- 生物制药.
- HQ
- 苏州市, 江苏省
Alphamab Oncology Questions
Alphamab Oncology's website is http://www.alphamabonc.com
Alphamab Oncology has
27 employees.
View email and phone details for 27
employees at Alphamab Oncology.
Alphamab Oncology's industry is
Pharmaceutical Manufacturing
Alphamab Oncology's top competitors are
Abtis | 앱티스,
Arrivent Biopharma,
Medilink Therapeutics,
Bioray Pharmaceutical,
Henlius,
Luye Pharma Group,
Biocytogen,
Beacon,
Innovent Biologics,
Hangzhou Dac Biotech Co., Ltd..
Alphamab Oncology's categories are Pharmaceutical Manufacturing
Alphamab Oncology's founding year is 2015
